ATE517105T1 - Neue imidazolon-derivate, wirkstoffpräparat daraus, pharmazeutische zusammensetzungen und ihre verwendung als hemmer von proteinkinasen, insbesondere cdc7 - Google Patents

Neue imidazolon-derivate, wirkstoffpräparat daraus, pharmazeutische zusammensetzungen und ihre verwendung als hemmer von proteinkinasen, insbesondere cdc7

Info

Publication number
ATE517105T1
ATE517105T1 AT07858418T AT07858418T ATE517105T1 AT E517105 T1 ATE517105 T1 AT E517105T1 AT 07858418 T AT07858418 T AT 07858418T AT 07858418 T AT07858418 T AT 07858418T AT E517105 T1 ATE517105 T1 AT E517105T1
Authority
AT
Austria
Prior art keywords
inhibitors
pharmaceutical compositions
active ingredients
protein kinases
imidazolone derivatives
Prior art date
Application number
AT07858418T
Other languages
German (de)
English (en)
Inventor
Vincent Leroy
Eric Bacque
Emmanuel Conseiller
Anke Steinmetz
Baptiste Ronan
Jean-Philippe Letallec
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of ATE517105T1 publication Critical patent/ATE517105T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT07858418T 2006-10-12 2007-10-10 Neue imidazolon-derivate, wirkstoffpräparat daraus, pharmazeutische zusammensetzungen und ihre verwendung als hemmer von proteinkinasen, insbesondere cdc7 ATE517105T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0608924A FR2907120B1 (fr) 2006-10-12 2006-10-12 Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7
PCT/FR2007/001651 WO2008046982A2 (fr) 2006-10-12 2007-10-10 Nouveaux derives imidazolones, leur preparation a titre de medicaments, compositions pharmaceutiques, utilisation comme inhibiteurs de proteines kinases notamment cdc7

Publications (1)

Publication Number Publication Date
ATE517105T1 true ATE517105T1 (de) 2011-08-15

Family

ID=37964098

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07858418T ATE517105T1 (de) 2006-10-12 2007-10-10 Neue imidazolon-derivate, wirkstoffpräparat daraus, pharmazeutische zusammensetzungen und ihre verwendung als hemmer von proteinkinasen, insbesondere cdc7

Country Status (29)

Country Link
US (1) US8314121B2 (sr)
EP (1) EP2094699B1 (sr)
JP (1) JP2010505922A (sr)
KR (1) KR101552361B1 (sr)
CN (1) CN101522678A (sr)
AR (1) AR063249A1 (sr)
AT (1) ATE517105T1 (sr)
AU (1) AU2007311833B2 (sr)
BR (1) BRPI0719790A2 (sr)
CA (1) CA2660166C (sr)
CL (1) CL2007002934A1 (sr)
CO (1) CO6160310A2 (sr)
CY (1) CY1112066T1 (sr)
DK (1) DK2094699T3 (sr)
EA (1) EA018496B1 (sr)
ES (1) ES2370049T3 (sr)
FR (1) FR2907120B1 (sr)
HR (1) HRP20110759T1 (sr)
IL (1) IL197452A (sr)
MA (1) MA30877B1 (sr)
MX (1) MX2009003283A (sr)
NO (1) NO20091486L (sr)
PL (1) PL2094699T3 (sr)
PT (1) PT2094699E (sr)
RS (1) RS51985B (sr)
SI (1) SI2094699T1 (sr)
TW (1) TW200821310A (sr)
UY (1) UY30642A1 (sr)
WO (1) WO2008046982A2 (sr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120024619A (ko) 2009-04-20 2012-03-14 에스비아이 바이오테크 가부시키가이샤 티아졸리디논 유도체
CA2767089A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
KR101851130B1 (ko) * 2009-12-04 2018-04-23 센화 바이오사이언시즈 인코포레이티드 Ｃｋ2 억제제로서 피라졸로피리미딘 및 관련된 헤테로사이클
EP2560971B1 (en) 2010-04-19 2014-04-09 Abbvie Inc. Pyrrolopyridines as inhibitors of kinases
US8742113B2 (en) 2011-03-31 2014-06-03 Sbi Biotech Co., Ltd. Furanone derivative
JP6569908B2 (ja) 2014-01-31 2019-09-04 カルナバイオサイエンス株式会社 抗がん剤組成物
GB201807147D0 (en) 2018-05-01 2018-06-13 Oncologica Uk Ltd Therapeutic combination
US12533353B2 (en) 2018-09-24 2026-01-27 Carna Biosciences, Inc. Methods of treatment of cancer comprising CDC7 inhibitors
EP4083037A4 (en) * 2019-12-26 2024-01-24 Yonsei University, University-Industry Foundation(UIF). Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or tau protein-associated diseases containing same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
EP2295433A3 (en) 2003-03-06 2011-07-06 Eisai R&D Management Co., Ltd. JNK inhibitors
DE602004014163D1 (de) * 2003-08-08 2008-07-10 Pfizer Italia Srl Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
TW200604168A (en) 2004-04-02 2006-02-01 Vertex Pharma Azaindoles useful as inhibitors of rock and other protein kinases
AU2005293831B2 (en) * 2004-10-14 2011-01-06 F. Hoffmann-La Roche Ag Novel Azaindole thiazolinones as anti-cancer agents
US7371862B2 (en) * 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
MX2009003283A (es) 2009-04-08
WO2008046982A3 (fr) 2008-06-19
HRP20110759T1 (hr) 2011-11-30
FR2907120A1 (fr) 2008-04-18
KR101552361B1 (ko) 2015-09-10
SI2094699T1 (sl) 2011-11-30
JP2010505922A (ja) 2010-02-25
TW200821310A (en) 2008-05-16
PT2094699E (pt) 2011-10-24
CY1112066T1 (el) 2015-11-04
RS51985B (sr) 2012-02-29
ES2370049T3 (es) 2011-12-12
EP2094699A2 (fr) 2009-09-02
UY30642A1 (es) 2008-05-31
EA018496B1 (ru) 2013-08-30
WO2008046982A2 (fr) 2008-04-24
MA30877B1 (fr) 2009-11-02
CA2660166C (fr) 2015-12-29
CN101522678A (zh) 2009-09-02
IL197452A0 (en) 2009-12-24
DK2094699T3 (da) 2011-11-07
IL197452A (en) 2015-10-29
AR063249A1 (es) 2009-01-14
KR20090064571A (ko) 2009-06-19
EP2094699B1 (fr) 2011-07-20
US8314121B2 (en) 2012-11-20
CL2007002934A1 (es) 2008-05-30
FR2907120B1 (fr) 2013-01-11
BRPI0719790A2 (pt) 2014-11-25
AU2007311833B2 (en) 2013-05-02
PL2094699T3 (pl) 2011-12-30
US20090253679A1 (en) 2009-10-08
NO20091486L (no) 2009-04-16
CO6160310A2 (es) 2010-05-20
CA2660166A1 (fr) 2008-04-24
AU2007311833A1 (en) 2008-04-24
EA200970364A1 (ru) 2009-10-30

Similar Documents

Publication Publication Date Title
ATE517105T1 (de) Neue imidazolon-derivate, wirkstoffpräparat daraus, pharmazeutische zusammensetzungen und ihre verwendung als hemmer von proteinkinasen, insbesondere cdc7
BRPI0515477A (pt) derivados heterocìclicos bicìclicos e o uso dos mesmos como inibidores de estaroil-coa-desaturase (scd)
EP2030974A4 (en) HETEROCYCLIC NON-NUCLEOSIDE COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE AS ANTIVIRAL AGENTS
BRPI0515489A (pt) derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase
BRPI0515478A (pt) derivados heterocìclicos e seu uso como mediadores de estearoil-coa-desaturase
ATE517621T1 (de) Verwendung von ampk-aktivierenden imidazol- derivaten, herstellungsverfahren dafür und diese enthaltende pharmazeutische zusammensetzungen
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
MX384206B (es) Formulaciones de inhibidores de dpp iv
BRPI0915084B8 (pt) composto, e, composição farmacêutica
DE602007005487D1 (de) Harnstoffderivate von tropan, ihre herstellung und ihre therapeutische anwendung
CY2015043I1 (el) Ενωσεις και συνθεσεις ως αναστολεις των πρωτεϊνικων κινασων
ATE492545T1 (de) Verbindungen und zusammensetzungen als proteinkinase-hemmer
ATE377597T1 (de) Anilinochinazoline als protein-tyrosin- kinasehemmer
BRPI0515500A (pt) derivados piridazina para inibição de estearoil-coa-desaturase
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
DE602005026395D1 (de) Neue zyklische harnstoffderivate, deren herstellung und pharmazeutische verwendung damit als kinase-inhibitoren
CL2011000230A1 (es) Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
BRPI0716495A2 (pt) (r,r)-fenoterol e análogos de (r,r)- ou (r,s)-fenoterol, uso dos mesmos na preparação de composição farmacêutica e composição farmacêutica compreendendo o referidos compostos.
EA200700142A1 (ru) Замещенные гетероциклом циклические производные мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы
BRPI0512938A (pt) derivados da quinazolinediona como inibidores parp
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
BRPI0820899A2 (pt) Formulação cosmética, e, uso da composição
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
BRPI0909296A2 (pt) uso de pelo menos um princípio ativo, e, composições cosmética, farmacêutica e/ou dermatológica
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2094699

Country of ref document: EP